Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B

Table 1 Baseline clinical characteristics of the different therapy groups and healthy controls

	HCs (n = 14)	LAM (n = 28)	LDT (n = 24)	P (LAM vs LDT)
Sex ratio (male/female)	11:3	26:2	18:6	NS
Age (mean ± SD)	40 ± 11.4	39.86 ± 10.9	34.71 ± 8.40	NS
ALT median (U/L, range)	30 (30-34)	145 (60-453)	227 (60-957)	NS
AST median (U/L, range)	23 (17-30)	87.5 (20-274)	129.5 (29-585)	NS
TBil median (μmol/L, range)	4.0 (3.0-7.0)	19.25 (7.7-35.6)	37.5 (35-47)	NS
Median albumin (g/dL, range)		3.6 (2.4-4.4)	3.7 (3.4-4.7)	NS
HBV DNA (Log10 IU/mL) (mean ± SD)		6.28 ± 0.78	5.85 ± 0.64	NS
HBeAg (PEIU/mL) (mean ± SD)		46.53 ± 48.63	53.91 ± 83.59	NS

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBil: Total bilirubin; HBV DNA: Hepatitis B virus deoxyribonucleic acid; HBeAg: Hepatitis B virus envelope antigen; HCs: Healthy controls; LAM: Lamivudine; LDT: Telbivudine; NS: Not significant.